Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021
Clinical Pharmacology & Therapeutics · 2023-12 · 114 (6) · 1285-1292
DOI: 10.1002/cpt.3034 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 16.10.2023. Verfasst von Renske J Grupstra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Ut…. Hauptthemen laut MEDLINE: Health Personnel, Pharmacovigilance. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The European Medicines Agency (EMA) supervises medicines' safe and effective use throughout the product's life cycle by, for example, monitoring the implementation of risk minimization measures (RMMs). Limited information is available on factors associated with effectiveness of RMMs. This study reviews post‐authorization safety studies (PASS) evaluating the effectiveness of RMMs assessed by the Pharmacovigilance Risk Assessment Committee (PRAC) between 2016 and 2021. PASS assessment reports finalized by PRAC between January 1, 2016, and December 31, 2021, were compiled from non‐public EMA databases and PASS characteristics were extracted. Of the 93 PASS included, 62.4% aimed to measure healthcare professionals' awareness, knowledge, and behavior regarding RMMs. There were 67.7% of the 93 PASS that used primary data, 24.7% used secondary data sources, and 7.5% used both. A cross‐sectional study design was most frequently applied (77.4%), followed by a cohort study design (29.0%). Nearly 40% of the included PASS did not render a conclusion on RMM effectiveness. Of the 60% that did render a conclusion, 82.1% were deemed effective. Only minor differences in characteristics were found when stratified by outcome (i.e., effective RMM, ineffective RMM, and no conclusion on RMM effectiveness). To conclude, 4 out of 10 PASS assessing impact of RMMs did not render a conclusion on RMM effectiveness. No clear differences in PASS characteristics were found in relation to their outcomes, indicating that additional research is needed to understand better the underlying reasons for PASS being inconclusive.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
- European Medicines Agency, Amsterdam, The Netherlands.
- Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
- Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland.
ORCID-Profile: Thomas Goedecke, Helga Gardarsdottir
Zitieren
APA
Grupstra, R. J., Goedecke, T., Scheffers, J., Strassmann, V., & Gardarsdottir, H. (2023). Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021. Clinical Pharmacology & Therapeutics, 114(6), 1285-1292. https://doi.org/10.1002/cpt.3034
Vancouver
Grupstra RJ, Goedecke T, Scheffers J, Strassmann V, Gardarsdottir H. Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021. Clinical Pharmacology & Therapeutics. 2023;114(6):1285-1292. doi:10.1002/cpt.3034
BibTeX
@article{Grupstra2023,
author = {Grupstra, Renske J and Goedecke, Thomas and Scheffers, Jet and Strassmann, Valerie and Gardarsdottir, Helga},
title = {Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
volume = {114},
number = {6},
pages = {1285--1292},
doi = {10.1002/cpt.3034}
}
EUVIMED